Literature DB >> 21658092

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.

Jean-Louis Montastruc1, Agnès Sommet, Haleh Bagheri, Maryse Lapeyre-Mestre.   

Abstract

Mesh：

Year:  2011        PMID： 21658092      PMCID： PMC3244636          DOI： 10.1111/j.1365-2125.2011.04037.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

Review 1.  The reporting odds ratio and its advantages over the proportional reporting ratio.

Authors:  Kenneth J Rothman; Stephan Lanes; Susan T Sacks
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

2.  Serum sickness-like reactions to cefaclor.

Authors:  B H Stricker; J G Tijssen
Journal:  J Clin Epidemiol       Date:  1992-10       Impact factor: 6.437

3.  Valproate and birth defects.

Authors:  E Robert; F Rosa
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

4.  Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

Authors:  Guillaume Montastruc; Sylvie Favreliere; Agnès Sommet; Atul Pathak; Maryse Lapeyre-Mestre; Marie-Christine Perault-Pochat; Jean-Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

5.  A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.

Authors:  Sofie Schwan; Anders Sundström; Elisabet Stjernberg; Ebba Hallberg; Pär Hallberg
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953

6.  Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.

Authors:  Francois Chavant; Sylvie Favrelière; Claire Lafay-Chebassier; Caroline Plazanet; Marie-Christine Pérault-Pochat
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

7.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

8.  Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

Authors:  A Sommet; S Grolleau; H Bagheri; M Lapeyre-Mestre; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2008-05-29       Impact factor: 2.953

9.  Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs.

Authors:  C Souyri; P Olivier; S Grolleau; M Lapeyre-Mestre
Journal:  Clin Exp Dermatol       Date:  2008-02-02       Impact factor: 3.470

10.  Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

Authors:  Carlo Piccinni; Domenico Motola; Giulio Marchesini; Elisabetta Poluzzi
Journal:  Diabetes Care       Date:  2011-04-22       Impact factor: 19.112
  10 in total
  88 in total

1.  A comparative study of QT prolongation with serotonin reuptake inhibitors.

Authors:  Ana Ojero-Senard; Justine Benevent; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Leila Chebane; Melanie Araujo; Francois Montastruc; Jean-Louis Montastruc
Journal:  Psychopharmacology (Berl)       Date:  2017-08-03       Impact factor: 4.530

2.  Safety profile of enantiomers vs. racemic mixtures: it's the same?

Authors:  Céline Caillet; Laurence Chauvelot-Moachon; Jean-Louis Montastruc; Haleh Bagheri
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Two cheers or three for treatment guidelines? Nudging prescribers in right directions.

Authors:  Yoon K Loke; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

4.  Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR.

Authors:  Franck Maschino; Caroline Hurault-Delarue; Leila Chebbane; Vincent Fabry; Jean Louis Montastruc; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

5.  Comment on: "Drug-Induced Hyperglycaemia and Diabetes".

Authors:  Jean-Louis Montastruc; Leila Chebane; Haleh Bagheri
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

6.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase®.

Authors:  Thi Thu Ha Nguyen; Anne Roussin; Vanessa Rousseau; Jean-Louis Montastruc; François Montastruc
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

7.  Detection of signals of abuse and dependence applying disproportionality analysis.

Authors:  V Pauly; M Lapeyre-Mestre; D Braunstein; M Rueter; X Thirion; E Jouanjus; J Micallef
Journal:  Eur J Clin Pharmacol       Date:  2014-11-20       Impact factor: 2.953

Review 8.  Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.

Authors:  Emilie Patras de Campaigno; Emmanuelle Bondon-Guitton; Guy Laurent; Francois Montastruc; Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Fabien Despas
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

9.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

10.  Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

Authors:  Stephen W Reese; Eugene Cone; Maya Marchese; Brenda Garcia; Wesley Chou; Asha Ayub; Kerry Kilbridge; Gerald Weinhouse; Quoc-Dien Trinh
Journal:  Lung       Date:  2021-02-22       Impact factor: 2.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.